查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1872122

Duchenne氏肌肉失养症：全球市场份额和排名、总收入和需求预测（2025-2031年）

Duchenne Muscular Dystrophy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 85 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球Duchenne氏肌肉失养症市场规模估计为 20.67 亿美元，预计到 2031 年将达到 44.49 亿美元，在预测期（2025-2031 年）内复合年增长率为 13.1%。

Duchenne氏肌肉失养症是一种X染色体连锁遗传疾病，主要影响男孩。患有杜氏肌肉营养不良症的男孩最早在2至5岁时就开始出现肌肉无力的征兆。这种疾病会逐渐削弱手臂、腿部和身体躯干的骨骼肌（随意肌）。由于进行性肌肉无力，杜氏肌肉营养不良症患者通常在7至13岁之间需要依靠轮椅出行。随着病情进展，呼吸肌肉和心肌也会受到影响，呼吸衰竭和心臟衰竭是许多患者的主要死因，患者通常在20岁之前去世。

全球Duchenne氏肌肉失养症市场的主要企业包括Sarepta Therapeutics和PTC Therapeutics。北美是最大的市场，占超过70%的市场份额，其次是欧洲和日本，各占25%以上的市场份额。以产品划分，Exondys 51是最大的细分市场，占超过55%的市场。按应用领域划分，医院是最大的应用领域，其次是诊所和居家医疗。

Duchenne氏肌肉失养症（DMD）市场主要受以下因素驱动：

1. 疾病负担与流行病学数据

  • 1.1 发病率和患者族群

全球数据：DMD 是一种 X 连锁遗传疾病，全球发生率约为每 10 万人 6 例。大多数患者为男性（由于 X 连锁隐性遗传，女性必须携带两个缺陷基因才会生病）。

中国数据：中国DMD的发生率约为1/3853，全国约有6万至7万名患者。多数患者为儿童及青少年，发病高峰年龄为3至5岁。

地理分布：欧洲（瑞典、挪威）、北美（美国、加拿大）和中国是盛行率最高的地区，约 30% 的临床试验在亚太地区（澳洲、日本等）进行。

  • 1.2 疾病的特征和影响

症状与预后：患者通常在2-3岁左右出现运动发育迟缓（例如，坐立和行走困难），12岁左右丧失行走能力，最终死于呼吸衰竭或心肺衰竭。平均寿命约40岁。併发症：约30%的患者会出现轻度智能障碍，骨骼畸形（例如，脊椎侧弯）和肌肉萎缩会显着影响生活品质。

2. 治疗进展及在研药物

  • 2.1 非处方药

皮质类固醇：皮质类固醇，如地夫可特（Emflaza）和伐洛酮，是传统的治疗方法，可透过其抗发炎特性减缓疾病进展，但它们也会引起副作用（如体重增加和生长抑制）。

外显子跳跃疗法：反义寡核苷酸（ASO）用于跳过突变外显子，部分恢復Dystrophin的功能。已通过核准的药物包括：

Exondis51（外显子 51 跳跃，影响 13% 的 DMD 患者）、Byondis53（外显子 53 跳跃，影响 8% 的患者）和 Amondis45（外显子 45 跳跃）。

Viltepsiso（外显子53跳跃疗法，由日本製药株式会社生产）。基因疗法：Erebdis（SRP-9001）是第一个核准用于治疗杜氏肌肉营养不良症（DMD）的基因疗法。它透过腺相关病毒（AAV）载体递送Dystrophin基因。预计其适应症将于2024年扩大至4岁以上患者（包括可行走和不可行走的患者）。

  • 2.2 正在研发的药物和技术

基因疗法：多家公司（包括 Sarepta Therapeutics 和 Roche）正在开发基因疗法来治疗潜在的遗传缺陷。

细胞疗法和基因编辑：基因编辑工具（例如 CRISPR 技术）在临床前试验中显示出令人鼓舞的结果，但尚未大规模应用。

HDAC抑制剂：例如，吉比司他（Duvyzat）可抑制组蛋白去乙酰化酶，从而减缓肌肉萎缩。它于2024年获得FDA核准，用于治疗6岁及以上患者。

3. 政策支持与孤儿药认定

  • 3.1 全球政策的差异

在美国，FDA已核准多种用于治疗杜氏肌肉营养不良症（DMD）的药物（例如Exondys 51和Erebdis），并加快了核准，但要求进行验证性试验以确认其疗效。欧盟拒绝续签部分药物（例如Exondys 51）的核准，而英国药品和保健产品监管署（MHRA）则维持了部分药物的供应，这反映了地区政策的差异。

中国已将杜氏肌肉营养不良症 (DMD) 指定为首个罕见疾病，提供专款支持研究和开发，并促进新药（如缬莫隆酮）的优先审查和报销。

  • 3.2 孤儿药激励措施

税收优惠和快速核准：许多国家透过指定制度（例如美国的孤儿药法案）提供税收优惠、研发补贴和快速核准，帮助公司降低研发风险。

安全网计画：一些国家（例如法国和德国）将对预算影响最小的药品免于经济分析，从而加速病患获得药品的速度。

4. 患者需求与组织活动

  • 4.1 患者的意愿和生活品质

不断变化的治疗需求：患者及其家属强烈希望找到能够减少传统荷尔蒙（包括新型分离性类固醇，如缬莫洛隆）副作用的治疗方法，这推动了创新疗法的研发。提高疾病认知度：患者团体（例如Duchenne氏肌肉失养症协会）正透过宣传活动提高大众对杜氏肌肉营养不良症的认知度，并呼吁提供更多治疗选择和医疗保险覆盖。

  • 4.2 优化临床管理

透过多学科协作进行全面管理：例如，北京儿童医院组建了一支神经科、復健科和心臟科等部门组成的DMD专家团队，提供终身个人化治疗。

早期诊断与介入：我们利用运动功能评估、肌肉酶谱分析（肌酸激酶水平升高 20-200 倍）和基因检测来确保早期诊断和优化治疗。

5. 资本投资与研发趋势

  • 5.1 製药公司的策略

大型国际公司：Sarepta Therapeutics（外显子跳跃疗法的领导者）、罗氏（基因疗法合作）和Italfarmaco（HDAC抑制剂）等公司正在推动创新治疗方法的开发。

中国企业：曙方药业（已在国内推出缬莫洛酮）、新芽基因和金维科正在投资基因治疗，并透过合作收购和独立研发将新药推向市场。 5.2创业投资及併购

资本趋势：从 2023 年到 2024 年，多家国际製药公司与中国 DMD 研发公司合作（例如，Cranberry Pharmaceuticals 推出学名药仿製药），以促进基因疗法等创新治疗方法的开发。

市场预测：预计从 2024 年到 2030 年，中国 DMD 药物市场将继续成长，创新治疗方法（例如基因疗法）有望主导市场并推动市场渗透率的提高。

6. 技术进步与未来方向

  • 6.1 基因治疗的进展

Elevidis 的突破性进展：作为首个针对杜氏肌肉营养不良症 (DMD) 的基因疗法，Elevidis 透过一次治疗即可解决其根本的遗传病因。儘管存在免疫反应和禁忌症方面的挑战，但它代表了未来的发展方向。

检验长期疗效：验证性试验（例如 EMBARK）将继续追踪患者的功能改善情况（例如 North Star 步态评估、站立时间），以检验基因疗法的持久性。

  • 6.2 个人化治疗与数位化

精准医疗：基于患者基因突变类型製定个人化治疗方案（例如外显子跳跃疗法）将提高治疗效果。数位化医疗应用：线上咨询和远端监测等技术（例如北京儿童医院的「绿色通道」系统）将优化病患管理，改善就医体验。

Duchenne氏肌肉失养症(DMD) 市场成长的主要驱动因素包括疾病负担、治疗进展（尤其是基因疗法）、政策支持、患者需求不断增长以及资本投资。展望未来，更多创新治疗方法的核准和医保覆盖范围的扩大预计将进一步刺激市场需求，推动基因疗法等前沿技术成为主流治疗方法。

本报告旨在按地区/国家、类型和应用对全球Duchenne氏肌肉失养症市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以收益为准，以2024年为基准年，对Duchenne氏肌肉失养症市场规模、估计值和预测进行了分析，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定Duchenne氏肌肉失养症业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

按类型分類的细分市场

  • 埃克森美孚51号
  • 恩弗拉扎
  • 特兰斯拉纳

应用领域

  • 医院
  • 诊所
  • 居家医疗

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Duchenne Muscular Dystrophy was estimated to be worth US$ 2067 million in 2024 and is forecast to a readjusted size of US$ 4449 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.

Duchenne Muscular Dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc. North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent. In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

The Duchenne muscular dystrophy (DMD) market is primarily driven by the following factors:

1. Disease Burden and Epidemiological Data

  • 1.1 Incidence and Patient Population

Global Data: DMD is a rare, X-linked genetic disease with a global incidence of approximately 6 cases per 100,000 people, with the majority of patients being male (due to recessive inheritance of the X chromosome, females require two defective copies to develop the disease).

China Data: The incidence of DMD in China is approximately 1 in 3,853, with approximately 60,000 to 70,000 patients nationwide. The majority of patients are children and adolescents, with the peak incidence occurring between the ages of 3 and 5 years.

Regional Distribution: Europe (Sweden and Norway), North America (the United States and Canada), and China are the most prevalent regions, with the Asia-Pacific region (such as Australia and Japan) contributing approximately 30% of clinical trials.

  • 1.2 Disease Characteristics and Impact

Symptoms and Prognosis: Patients typically experience delayed motor development (e.g., difficulty sitting and walking) at 2-3 years of age, lose the ability to walk around 12 years of age, and ultimately die from respiratory or cardiopulmonary failure. The average life expectancy is approximately 40 years. Complications: Approximately 30% of patients experience mild intellectual disability, and skeletal deformities (such as scoliosis) and muscle atrophy significantly impact their quality of life.

2. Treatment Advances and Drugs in Development

  • 2.1 Marketed Drugs

Corticosteroids: Corticosteroids such as deflazacort (Emflaza) and vamorolone are traditional treatments that slow disease progression through their anti-inflammatory effects, but they can also cause side effects (such as weight gain and growth suppression).

Exon-skipping therapy: Antisense oligonucleotides (ASOs) are used to skip the mutated exon, restoring some dystrophin function. Approved drugs include:

Exondys 51 (exon 51 skipping, affecting 13% of DMD patients), Vyondys 53 (exon 53 skipping, affecting 8%), and Amondys 45 (exon 45 skipping).

Viltepsiso (exon 53 skipping, manufactured by Nippon Shinyaku Co., Ltd.). Gene Therapy: Elevidys (SRP-9001) is the first approved gene therapy for DMD. It delivers the dystrophin gene via an AAV vector. Its indication will be expanded to patients aged 4 years and older (regardless of ambulatory status) in 2024.

  • 2.2 Drugs and Technologies in Development

Gene Therapy: Several companies (such as Sarepta Therapeutics and Roche) are advancing gene therapies to address the underlying genetic defect.

Cell Therapy and Gene Editing: Gene editing tools such as CRISPR technology have shown promise in preclinical studies but have yet to enter large-scale application.

HDAC inhibitors: For example, givinostat (Duvyzat) inhibits histone deacetylases to slow muscle degeneration and was approved by the FDA in 2024 for patients aged 6 years and older.

3. Policy Support and Orphan Drug Designation

  • 3.1 Global Policy Differences

US: The FDA has approved several DMD drugs (such as Exondys 51 and Elevidys) through accelerated approval, but requires confirmatory trials to verify efficacy. The European Union (EU) has refused to renew approval for some drugs (such as Exondys 51), while the UK's MHRA has retained access to some drugs, reflecting regional policy differences.

China has included DMD in its first list of rare diseases, providing dedicated funding to support research and development, and promoting priority review and reimbursement of new drugs (such as valmorolone).

  • 3.2 Orphan Drug Incentives

Tax Incentives and Expedited Approval: Most countries use orphan drug designation (such as the US Orphan Drug Act) to provide tax breaks, research and development subsidies, and fast-track approvals, reducing R&D risks for companies.

Safety Net Programs: Some countries (such as France and Germany) waive economic analysis for drugs with minimal budgetary impact, accelerating patient access.

4. Patient Needs and Organizational Activities

  • 4.1 Patient Demands and Quality of Life

Evolving Treatment Needs: Patients and families have a strong demand for treatments that reduce the side effects of traditional hormones (such as newer dissociative steroids like valmorolone), driving the development of innovative therapies. Raising Disease Awareness: Patient organizations (such as the Duchenne Muscular Dystrophy Association) are raising public awareness of DMD through advocacy, advocating for more treatment options and medical insurance coverage.

  • 4.2 Optimizing Clinical Management

Multidisciplinary Integrated Management: For example, Beijing Children's Hospital has established a multidisciplinary DMD team (including neurology, rehabilitation, and cardiology) to provide personalized treatment throughout the lifespan.

Early Diagnosis and Intervention: Motor function assessments, muscle enzyme profiles (creatine kinase elevation of 20-200 times), and genetic testing are used to achieve early diagnosis and optimize the therapeutic window.

5. Capital Investment and R&D Trends

  • 5.1 Pharmaceutical Company Strategies

International giants: Sarepta Therapeutics (leading in exon skipping therapies), Roche (gene therapy collaborations), Italfarmaco (HDAC inhibitors), and other companies are driving the development of innovative therapies.

Chinese companies: Shufang Pharmaceuticals (valmorolone launched domestically), New Sprout Gene, and Jinweike are investing in gene therapy, bringing new drugs to market through collaborative acquisitions or independent R&D. 5.2 Venture Capital and M&A

Capital Activity: In 2023-2024, several international pharmaceutical companies entered into collaborations with Chinese DMD R&D companies (e.g., Cranbury Pharmaceuticals introduced generic versions of deflazacort), promoting the development of innovative therapies such as gene therapy.

Market Forecast: China's DMD drug market is expected to continue to grow from 2024 to 2030, with innovative therapies (e.g., gene therapy) dominating the market and driving increased market penetration.

6. Technological Advances and Future Directions

  • 6.1 Gene Therapy Breakthroughs

Elevidys' Milestone: As the first DMD gene therapy, Elevidys addresses the underlying genetic cause with a one-time treatment. Despite challenges with immunity and contraindications, it represents a future direction.

Long-Term Efficacy Verification: Confirmatory trials (e.g., the EMBARK trial) will continuously track patient functional improvements (e.g., North Star Walk Assessment, Time to Stand), verifying the durability of gene therapy.

  • 6.2 Personalized Treatment and Digitalization

Precision Medicine: Developing personalized treatment plans based on the patient's genetic mutation type (e.g., exon skipping therapy) improves efficacy. Digital healthcare applications: Technologies such as online diagnosis and treatment, remote monitoring (such as the "Green Channel" system at Beijing Children's Hospital) optimize patient management and enhance the medical experience.

The growth of the Duchenne muscular dystrophy (DMD) market is primarily driven by the disease burden, treatment advances (particularly gene therapy), policy support, escalating patient needs, and capital investment. In the future, with the approval of more innovative therapies and expanded medical insurance coverage, market demand will be further unleashed, and cutting-edge technologies such as gene therapy are expected to become mainstream treatments.

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Duchenne Muscular Dystrophy by region & country, by Type, and by Application.

The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.

Market Segmentation

By Company

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Segment by Type

  • Exondys 51
  • Emflaza
  • Translarna

Segment by Application

  • Hospitals
  • Clinics
  • Home Care

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Duchenne Muscular Dystrophy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Duchenne Muscular Dystrophy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Duchenne Muscular Dystrophy Product Introduction
  • 1.2 Global Duchenne Muscular Dystrophy Market Size Forecast (2020-2031)
  • 1.3 Duchenne Muscular Dystrophy Market Trends & Drivers
    • 1.3.1 Duchenne Muscular Dystrophy Industry Trends
    • 1.3.2 Duchenne Muscular Dystrophy Market Drivers & Opportunity
    • 1.3.3 Duchenne Muscular Dystrophy Market Challenges
    • 1.3.4 Duchenne Muscular Dystrophy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Duchenne Muscular Dystrophy Players Revenue Ranking (2024)
  • 2.2 Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025)
  • 2.3 Key Companies Duchenne Muscular Dystrophy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Duchenne Muscular Dystrophy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy
  • 2.6 Duchenne Muscular Dystrophy Market Competitive Analysis
    • 2.6.1 Duchenne Muscular Dystrophy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Duchenne Muscular Dystrophy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Exondys 51
    • 3.1.2 Emflaza
    • 3.1.3 Translarna
  • 3.2 Global Duchenne Muscular Dystrophy Sales Value by Type
    • 3.2.1 Global Duchenne Muscular Dystrophy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Duchenne Muscular Dystrophy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Duchenne Muscular Dystrophy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Home Care
  • 4.2 Global Duchenne Muscular Dystrophy Sales Value by Application
    • 4.2.1 Global Duchenne Muscular Dystrophy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Duchenne Muscular Dystrophy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Duchenne Muscular Dystrophy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Duchenne Muscular Dystrophy Sales Value by Region
    • 5.1.1 Global Duchenne Muscular Dystrophy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Duchenne Muscular Dystrophy Sales Value by Region (2020-2025)
    • 5.1.3 Global Duchenne Muscular Dystrophy Sales Value by Region (2026-2031)
    • 5.1.4 Global Duchenne Muscular Dystrophy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.2.2 North America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.3.2 Europe Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Duchenne Muscular Dystrophy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.5.2 South America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Duchenne Muscular Dystrophy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Duchenne Muscular Dystrophy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.3.2 United States Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.4.2 Europe Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.5.2 China Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.6.2 Japan Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.7.2 South Korea Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.9.2 India Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Sarepta Therapeutics
    • 7.1.1 Sarepta Therapeutics Profile
    • 7.1.2 Sarepta Therapeutics Main Business
    • 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Sarepta Therapeutics Recent Developments
  • 7.2 PTC Therapeutics
    • 7.2.1 PTC Therapeutics Profile
    • 7.2.2 PTC Therapeutics Main Business
    • 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 PTC Therapeutics Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.3.4 Pfizer Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Bristol-Myers Squibb Profile
    • 7.4.2 Bristol-Myers Squibb Main Business
    • 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Bristol-Myers Squibb Recent Developments
  • 7.5 Italfarmaco
    • 7.5.1 Italfarmaco Profile
    • 7.5.2 Italfarmaco Main Business
    • 7.5.3 Italfarmaco Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.5.4 Italfarmaco Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Italfarmaco Recent Developments
  • 7.6 Santhera Pharmaceuticals
    • 7.6.1 Santhera Pharmaceuticals Profile
    • 7.6.2 Santhera Pharmaceuticals Main Business
    • 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Santhera Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Duchenne Muscular Dystrophy Industrial Chain
  • 8.2 Duchenne Muscular Dystrophy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Duchenne Muscular Dystrophy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Duchenne Muscular Dystrophy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Duchenne Muscular Dystrophy Market Trends
  • Table 2. Duchenne Muscular Dystrophy Market Drivers & Opportunity
  • Table 3. Duchenne Muscular Dystrophy Market Challenges
  • Table 4. Duchenne Muscular Dystrophy Market Restraints
  • Table 5. Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Duchenne Muscular Dystrophy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Duchenne Muscular Dystrophy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy
  • Table 10. Global Duchenne Muscular Dystrophy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Duchenne Muscular Dystrophy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Duchenne Muscular Dystrophy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Duchenne Muscular Dystrophy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Duchenne Muscular Dystrophy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Duchenne Muscular Dystrophy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Duchenne Muscular Dystrophy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Duchenne Muscular Dystrophy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Duchenne Muscular Dystrophy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Duchenne Muscular Dystrophy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Duchenne Muscular Dystrophy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Duchenne Muscular Dystrophy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Sarepta Therapeutics Basic Information List
  • Table 32. Sarepta Therapeutics Description and Business Overview
  • Table 33. Sarepta Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Sarepta Therapeutics (2020-2025)
  • Table 35. Sarepta Therapeutics Recent Developments
  • Table 36. PTC Therapeutics Basic Information List
  • Table 37. PTC Therapeutics Description and Business Overview
  • Table 38. PTC Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of PTC Therapeutics (2020-2025)
  • Table 40. PTC Therapeutics Recent Developments
  • Table 41. Pfizer Basic Information List
  • Table 42. Pfizer Description and Business Overview
  • Table 43. Pfizer Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Pfizer (2020-2025)
  • Table 45. Pfizer Recent Developments
  • Table 46. Bristol-Myers Squibb Basic Information List
  • Table 47. Bristol-Myers Squibb Description and Business Overview
  • Table 48. Bristol-Myers Squibb Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Bristol-Myers Squibb (2020-2025)
  • Table 50. Bristol-Myers Squibb Recent Developments
  • Table 51. Italfarmaco Basic Information List
  • Table 52. Italfarmaco Description and Business Overview
  • Table 53. Italfarmaco Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Italfarmaco (2020-2025)
  • Table 55. Italfarmaco Recent Developments
  • Table 56. Santhera Pharmaceuticals Basic Information List
  • Table 57. Santhera Pharmaceuticals Description and Business Overview
  • Table 58. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Santhera Pharmaceuticals (2020-2025)
  • Table 60. Santhera Pharmaceuticals Recent Developments
  • Table 61. Key Raw Materials Lists
  • Table 62. Raw Materials Key Suppliers Lists
  • Table 63. Duchenne Muscular Dystrophy Downstream Customers
  • Table 64. Duchenne Muscular Dystrophy Distributors List
  • Table 65. Research Programs/Design for This Report
  • Table 66. Key Data Information from Secondary Sources
  • Table 67. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Duchenne Muscular Dystrophy Product Picture
  • Figure 2. Global Duchenne Muscular Dystrophy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Duchenne Muscular Dystrophy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Duchenne Muscular Dystrophy Report Years Considered
  • Figure 5. Global Duchenne Muscular Dystrophy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Duchenne Muscular Dystrophy Revenue in 2024
  • Figure 7. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Exondys 51 Picture
  • Figure 9. Emflaza Picture
  • Figure 10. Translarna Picture
  • Figure 11. Global Duchenne Muscular Dystrophy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Duchenne Muscular Dystrophy Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Hospitals
  • Figure 14. Product Picture of Clinics
  • Figure 15. Product Picture of Home Care
  • Figure 16. Global Duchenne Muscular Dystrophy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Duchenne Muscular Dystrophy Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Duchenne Muscular Dystrophy Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Duchenne Muscular Dystrophy Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value (%), (2020-2031)
  • Figure 29. United States Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Duchenne Muscular Dystrophy Industrial Chain
  • Figure 51. Duchenne Muscular Dystrophy Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed